MedPath

UNIVERSITY OF SOUTHERN CALIFORNIA

UNIVERSITY OF SOUTHERN CALIFORNIA logo
🇺🇸United States
Ownership
Private
Established
1880-01-01
Employees
10K
Market Cap
-
Website
http://startusc.com

Vaccine Therapy in Treating Patients With Stage IIC-IV Melanoma

Phase 2
Completed
Conditions
Recurrent Intraocular Melanoma
Recurrent Melanoma
Stage IIIC Melanoma
Ciliary Body and Choroid Melanoma, Small Size
Stage IIIA Melanoma
Stage IIIB Intraocular Melanoma
Extraocular Extension Melanoma
Iris Melanoma
Ciliary Body and Choroid Melanoma, Medium/Large Size
Stage IIIB Melanoma
Interventions
Biological: gp100 antigen
Biological: tyrosinase peptide
Biological: recombinant MAGE-3.1 antigen
Biological: multi-epitope melanoma peptide vaccine
Biological: incomplete Freund's adjuvant
Drug: Montanide ISA 51 VG
Drug: agatolimod sodium
Other: laboratory biomarker analysis
First Posted Date
2004-06-11
Last Posted Date
2014-05-22
Lead Sponsor
University of Southern California
Target Recruit Count
42
Registration Number
NCT00085189
Locations
🇺🇸

University of Southern California, Los Angeles, California, United States

IM-862 in Treating Patients With Recurrent Ovarian Cancer

Phase 1
Completed
Conditions
Ovarian Cancer
First Posted Date
2004-06-03
Last Posted Date
2014-05-22
Lead Sponsor
University of Southern California
Target Recruit Count
43
Registration Number
NCT00003773
Locations
🇺🇸

USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States

Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma

Phase 1
Terminated
Conditions
Intraocular Melanoma
Melanoma (Skin)
First Posted Date
2004-05-26
Last Posted Date
2014-05-22
Lead Sponsor
University of Southern California
Target Recruit Count
15
Registration Number
NCT00005841
Locations
🇺🇸

USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States

🇺🇸

City of Hope National Medical Center, Los Angeles, California, United States

Vaccine Therapy in Treating Patients With Stage II Melanoma That Can Be Removed by Surgery

Phase 2
Completed
Conditions
Melanoma (Skin)
First Posted Date
2004-03-22
Last Posted Date
2014-05-22
Lead Sponsor
University of Southern California
Target Recruit Count
48
Registration Number
NCT00003274
Locations
🇺🇸

University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States

🇺🇸

USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles, California, United States

Chemotherapy Plus IM-862 in Treating Patients With Metastatic Colorectal Cancer

Phase 2
Terminated
Conditions
Colorectal Cancer
First Posted Date
2004-02-26
Last Posted Date
2014-05-22
Lead Sponsor
University of Southern California
Target Recruit Count
18
Registration Number
NCT00006037
Locations
🇺🇸

USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles, California, United States

Combination Chemotherapy in Treating Patients With Platinum-Resistant Recurrent Ovarian Cancer

Phase 2
Completed
Conditions
Ovarian Cancer
First Posted Date
2003-09-24
Last Posted Date
2014-05-22
Lead Sponsor
University of Southern California
Target Recruit Count
35
Registration Number
NCT00003449
Locations
🇺🇸

USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles, California, United States

Vaccine Therapy Followed by Biological Therapy in Treating Patients With Stage III or Stage IV Melanoma

Phase 2
Terminated
Conditions
Melanoma (Skin)
First Posted Date
2003-01-27
Last Posted Date
2014-05-22
Lead Sponsor
University of Southern California
Target Recruit Count
25
Registration Number
NCT00006113
Locations
🇺🇸

USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles, California, United States

Monoclonal Antibody and Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Has Been Removed During Surgery

Phase 1
Completed
Conditions
Melanoma (Skin)
Intraocular Melanoma
First Posted Date
2003-01-27
Last Posted Date
2014-05-22
Lead Sponsor
University of Southern California
Target Recruit Count
19
Registration Number
NCT00025181
Locations
🇺🇸

USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles, California, United States

Vaccine Therapy and Interleukin-12 With Either Alum or Sargramostim After Surgery in Treating Patients With Melanoma

Phase 2
Completed
Conditions
Intraocular Melanoma
Melanoma (Skin)
First Posted Date
2003-01-27
Last Posted Date
2014-05-22
Lead Sponsor
University of Southern California
Target Recruit Count
60
Registration Number
NCT00031733
Locations
🇺🇸

USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles, California, United States

Safety and Efficacy of Targeted Gene Transfer in Colorectal Cancer Metastatic to Liver

Phase 1
Withdrawn
Conditions
Colorectal Neoplasms
First Posted Date
2002-05-07
Last Posted Date
2014-05-22
Lead Sponsor
University of Southern California
Registration Number
NCT00035919
© Copyright 2025. All Rights Reserved by MedPath